Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00791518 · ClinicalTrials.gov registry record
Evaluation of Lung Function and Symptoms in Patients Diagnosed With Chronic Obstructive Pulmonary Disease (COPD) on Long-Acting Bronchodilator Monotherapy
A clinical trial of Pulmonary Disease, Chronic Obstructive, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- 1,084
- Enrollment target
- 20
- Study locations
NCT00791518 is a study of Pulmonary Disease, Chronic Obstructive that has completed, run by GlaxoSmithKline. The registered enrollment target is 1,084 participants, roughly in line with the 1,029-participant average among 74 other Pulmonary Disease, Chronic Obstructive trials with a reported enrollment target. The trial reports 20 study locations across 7 states.
The verdict
NCT00791518, a study of Pulmonary Disease, Chronic Obstructive, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- 1,084 participants
- Enrollment target
- 20
- Study locations
Study Summary
A multicenter study to evaluate lung function and symptoms in subjects with COPD who have been on regular use of only one long-acting bronchodilator.
Conditions Studied
Interventions
- DRUG No intervention
Study Locations (20)
Florida
- GSK Investigational Site - Cocoa
- GSK Investigational Site - DeLand
- GSK Investigational Site - Largo
- GSK Investigational Site - Miami
- GSK Investigational Site - Miami
- GSK Investigational Site - Naranja
- GSK Investigational Site - South Miami
- GSK Investigational Site - Tamarac
- GSK Investigational Site - Tampa
California
- GSK Investigational Site - National City
- GSK Investigational Site - Rancho Mirage
- GSK Investigational Site - Riverside
- GSK Investigational Site - Santa Ana
- GSK Investigational Site - Walnut Creek
Colorado
- GSK Investigational Site - Colorado Springs
- GSK Investigational Site - Colorado Springs
Alabama
- GSK Investigational Site - Birmingham
Arizona
- GSK Investigational Site - Tucson
Arkansas
- GSK Investigational Site - Little Rock
Connecticut
- GSK Investigational Site - Stamford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,084 participants |
| Start Date | 2008-12 |
| Est. Completion | 2009-05 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00791518
The ClinicalTrials.gov registry entry for NCT00791518 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,084 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 1,029-participant average among 74 other Pulmonary Disease, Chronic Obstructive trials with a reported enrollment target. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pulmonary Disease, Chronic Obstructive appearing as the primary indexed condition, and to 1 intervention - of which No intervention is the first listed.
NCT00791518 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Florida, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT00791518 about?
NCT00791518 is a clinical study titled "Evaluation of Lung Function and Symptoms in Patients Diagnosed With Chronic Obstructive Pulmonary Disease (COPD) on Long-Acting Bronchodilator Monotherapy". A multicenter study to evaluate lung function and symptoms in subjects with COPD who have been on regular use of only one long-acting bronchodilator.
What is the current status of trial NCT00791518?
This trial is currently completed. The enrollment target is 1,084 participants. The study started on 2008-12. Estimated completion is 2009-05.
What conditions does trial NCT00791518 study?
This clinical trial studies the following conditions: Pulmonary Disease, Chronic Obstructive.
What interventions are being tested in trial NCT00791518?
The interventions under investigation include: No intervention (DRUG).
Who is sponsoring clinical trial NCT00791518?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00791518 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Disease, Chronic Obstructive
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)
RECRUITING · Phase 3
-
A Study for GSK3862995B in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease
RECRUITING · Phase 1
-
Pragmatic Trial to Enhance Quality Safety, and Patient Experience in COPD
RECRUITING · NA
-
eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
RECRUITING · Phase 3
-
Trial to Determine Effective Aspirin Dose in COPD
RECRUITING · Phase 3
-
Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA -1)
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.